Pharmather Holdings Ltd · CSE:PHRM
Pharmather — Investor Presentation (October 2026)
27 slides from Pharmather's investor presentation, October 2026
Slide 1: 3D Printing of Personalized Medicine
3D Printing of Personalized Medicine. pharmather.com · m3dicines.com Corporate Presentation · October 2026 CSE: PHRM | OTCQB: PHRRF
Slide 2: Forward-Looking Statements
IM POR TA NT NOT ICE Forward-Looking Statements This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation with respect to PharmaTher Holdings Ltd. (the “Company”). All information other than statements of historical fact is forward-look
Slide 3: Pharmaceutical 3D printing for personalized medicine
WH O WE AR E Pharmaceutical 3D printing for personalized medicine. PLATFORM M3DICINES Validated formulations · GMP-ready CraftMake printing · Any dose, release or combination Any dose. PI PEL I NE Any release. Proprietary products Any combination — 503A peptides & ketamine · Rare & ultra-rare · Psyc
Slide 4: Medicine is made for everyone. We make it for one.
OUR M ISSION Medicine is made for everyone. We make it for one. CSE: PHRM | OTCQB: PHRRF
Slide 5: Mass manufacturing leaves many patients poorly served
WH Y 3D -PR IN TED M ED ICINE S MA TT ER Mass manufacturing leaves many patients poorly served. Conventional manufacturing pays off only at hundreds of thousands to millions of identical units. Personalized doses Often only injections or a few fixed strengths Children and rare diseases Adult tablets
Slide 6: The exact dose, for the specific patient, on demand — economically
WH Y PHAR M AC EUT ICAL 3 D PR IN TIN G The exact dose, for the specific patient, on demand — economically. Five things mass production can’t do economically — and why each one creates value. Batch size Dose Pill design Process Where it’s made 10 mg 20 mg 40 mg TOD AY Heat Pressure UV Overseas Patie
Slide 7: M3DICINES 3D-printed medicines
OUR PLA TFORM M3DICINES 3D-printed medicines. DIGIT A L RE C IPE 4 · A LR EA D Y P R I NT I NG Patient 10–15 kg band 8 dosage forms · 4 release profiles Dose 250 µg · ±1% Layers A enteric · B IR Format Taste-masked ODT Blend GRAS Geometry Batch Digital, per dose Beads & mini-ta blets Dual-print tabl
Slide 8: Exclusive North American distributor of CraftMake pharmaceutical 3D printing
COM M ER CIAL F OUN DA TION Exclusive North American distributor of CraftMake pharmaceutical 3D printing. 10,000+ potential M3DICINES Network sites across North America (management estimate). WHA T WE D IS T R IB UT E NE T W OR K P AR T N E R S A ND C US T OM E R S • CraftMake printers: enclosed, GM
Slide 9: Regulation, demand, technology and preparedness are converging
WH Y NOW Regulation, demand, technology and preparedness are converging. US$141B → US$295B US$567B → US$1.2T US$41B → US$59B Peptide therapeutics market, Global personalized-medicine market, Medical countermeasures market, 2025 → 2033 2024 → 2033 2025 → 2030 MEDIC A L REG U LA TIO N IS MO VI NG DEMA
Slide 10: Two pillars. One platform.
BUSIN ESS M ODEL Two pillars. One platform. WE OWN the products, formulations and network. WE OPEN the platform to partners. P I L L A R 1 · P RO DU C T P I P E L IN E P I L L A R 2 · P A RT N E RI NG & T EC HN O L O GY Personalized 503A products, including peptides and ketamine Network placements:
Slide 11: Five pipeline areas. One printing platform.
P R O D U C T P I P E L IN E Five pipeline areas. One printing platform. Where a precise dose, a combination or a small batch makes a medicine possible. P R O G RA M PA T HW AY S TATUS N E X T M I L ES T O N E 503A personalized products Q4 2026 first launches 503A compounding LA U N CH PL AN N E D N
Slide 12: From injection to a printed oral dose
PR O DUCT SPO TLIGHT · 5 03 A PER SO NA LIZED PR O DUCTS From injection to a printed oral dose. Today’s 503A-eligible peptides are prescribed and compounded through U.S. telehealth platforms, mostly as injections. We print them as chewables, dissolvable tablets and multi-layer combinations, each mad
Slide 13: One ketamine formulation, two markets
PR O DUCT SPO TLIGHT · KE TA MIN E One ketamine formulation, two markets. K E T A M I N E OD T Printed dissolvable tablet Dissolves in the mouth — no water, no needle. Printed size sets the dose; the formulation stays 10 mg 25 mg 50 mg 75 mg 100 mg the same. T E L E HE A L T H 10–100 mg in fine incr
Slide 14: Dose precision is the product
F D A P RO D U CT S PO T LIGH T · R A RE PED IA TR IC D IS E AS E PRO G RA M Dose precision is the product. Children with rare diseases are often dosed from adult tablets cut at home. L E A D F D A - T R AC K PR OG R A M · 5 0 5 ( b ) (1 ) · OR P H A N + P R I O R I T Y R E V I E W VO U C H E R TOD
Slide 15: Approval can earn a priority review voucher
THE PRV OPPORTU N ITY Approval can earn a priority review voucher — a potential US$100M+ asset. WH A T R A R E P E D I A T R I C VO U C H E R S H AV E S OL D FO R ( U S $ M I L L I ON S , R E P OR T E D ) H OW T HE I N CE N T I VE S WOR K $350 Orphan Drug Designation 1 7 years of market exclusivity,
Slide 16: Three underserved markets where small-batch production is an advantage
PIPE LINE EX PAN SION Three underserved markets where small-batch production is an advantage. Each is too small for a production line, and exactly right for pharmaceutical 3D printing. E V A LU AT I N G P LAN N E D E V A LU AT I N G Ultra-rare diseases Psychedelic medicines Discontinued & short-supp
Slide 17: A national medicines network
M 3D ICINES N AT I ON A L NE TWO R K P R O G RA M A national medicines network. Qualified sites make medicines close to the patients who need them. Remote areas 1 · Validate Provincial / PharmaTher and partners validate M3DICINES formulations and recipes regional nodes PharmaTher control site 2 · Qu
Slide 18: Built on the network, not on selling as many printers as possible
M 3D ICINES N ETW O RK · B US IN ES S M O D EL Built on the network, not on selling as many printers as possible. 1 · P LA C E + 1 NO DE 2 · L IC ENSE 3 · SE LL Network placements M3DICINES product offerings White-label programs CraftMake systems placed as network Validated formulations for 503A com
Slide 19: Commercial work in peacetime. Countermeasures in an emergency.
N AT I ON A L EM ER G EN C Y P R EP A R ED N ES S N O D E N ETW O R K · P L A N NED Commercial work in peacetime. Countermeasures in an emergency. Stockpile the inputs, not the pills. T O D A Y' S S T O CK P I L E S IN P EA C ETI ME IN A N EME RGENC Y Finished medicines in a few standard Nodes do co
Slide 20: An asset-light model with three partners, already in place
EX ECU TIO N FO O T PRIN T An asset-light model with three partners, already in place. H A R D WA R E DISP ENSI NG A ND R&D M A N U F A CT U R I N G Exclusive North American distributor Center of Excellence GMP contract manufacturer CraftMake systems, software, materials and PD Labs: a U.S. national
Slide 21: Non-dilutive upside outside the 3D printing core
STRA TEGIC A SSET S Non-dilutive upside outside the 3D printing core. Ketamine ANDA payments expected to begin Q1 2027. Other assets available to license, sell, partner or spin out. Ketamine ANDA KetaVault Ketamine patch KetaMist® Sairiyo Therapeutics FDA-approved ketamine CMC package, INDs, protoco
Slide 22: How our revenue stacks — each layer builds on the last
POTE NT IAL R EV EN UE M ODE L How our revenue stacks — each layer builds on the last. Revenue layers are designed to build on each other — all from the same M3DICINES platform, formulations and data. Approvals add step-change value Priority review voucher sale — potential US$100M+ A rare pediatric
Slide 23: Prove. Build. Lead.
M ILESTON ES Prove. Build. Lead. P RO V E 0–1 2 M ON THS BU I L D 1 2–3 6 M ON THS L EA D BE YO ND First 503A launches Q4 2026; ketamine dissolvable New programs: ultra-rare, psychedelic, Products tablet Q1 2027 discontinued and short-supply Expanded product and systems portfolio M3DICINES Network l
Slide 24: Our Team
OUR T EAM Leadership across drug development, FDA approvals, commercialization, manufacturing and capital markets. CS Fabio Chianelli Carmelo Marrelli Dr. Beverly J. Incledon Carlo Sansalone Founder, Chairman & CEO Chief Financial Officer Director Director 25+ years in specialty life sciences and Pu
Slide 25: Capital structure
COM PA NY Capital structure As at September 30, 2026 91,019,065 1,500,000 ~19% Issued and outstanding common shares Stock options outstanding Insider ownership PHRM (CSE) PHRRF (OTCQB) COMPANY F ACTS Transfer agent Auditor Fiscal year-end Filings Marrelli Trust Company Limited Truster Zweig Raithath
Slide 26: The opportunity in front of us
S UM M A RY The opportunity in front of us. T H E T AR GE T 1 Large markets and a national US$295B US$1.2T US$59B 10,000+ Peptide therapeutics Personalized medicine Medical countermeasures Potential network sites network Commercial work in peacetime; by 2033 · up from US$141B by 2033 · up from US$56
Slide 27: Thank You
Thank You info@pharmather.com · 1-888-846-3171 PharmaTher Holdings Ltd. pharmather.com · m3dicines.com Become an M3DICINES Network Partner: m3dicines.com · partners@m3dicines.com CSE: PHRM | OTCQB: PHRRF
PharmaTher Holdings — Investor Presentation (October 2026) on 6ix